No conflicts of interest were declared.
Stem cell transplantation as a therapy for cardiac fibrosis
Article first published online: 28 NOV 2012
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
The Journal of Pathology
Volume 229, Issue 2, pages 347–354, January 2013
How to Cite
Elnakish, M. T., Kuppusamy, P. and Khan, M. (2013), Stem cell transplantation as a therapy for cardiac fibrosis. J. Pathol., 229: 347–354. doi: 10.1002/path.4111
- Issue published online: 12 DEC 2012
- Article first published online: 28 NOV 2012
- Accepted manuscript online: 26 SEP 2012 06:37AM EST
- Manuscript Accepted: 12 SEP 2012
- Manuscript Revised: 26 AUG 2012
- Manuscript Received: 4 AUG 2012
- myocardial infarction;
- stem cell therapy;
- cardiac fibrosis
Cardiac fibrosis is a fundamental constituent of most cardiac pathologies and represents the upshot of nearly all types of cardiac injury. Generally, fibrosis is a scarring process, characterized by accumulation of fibroblasts and deposition of increasing amounts of extracellular matrix (ECM) proteins in the myocardium. Therapeutic approaches that control fibroblast activity and evade maladaptive processes could represent a potential strategy to attenuate progression towards heart failure. Currently, cell therapy is actively perceived as an alternative to traditional pharmacological management of myocardial infarction (MI). The majority of the studies applying stem cell therapy following MI have demonstrated a decline in fibrosis. However, it was not clearly recognized whether the decline in cardiac fibrosis was due to replacement of dead cardiomyocytes or because of the direct effects of paracrine factors released from the transplanted stem cells on the ECM. Therefore, the main focus of this review is to discuss the impact of different types of stem cells on cardiac fibrosis and associated cardiac remodelling in a variety of experimental models of heart failure, particularly MI.